We have now identified a family of orally administered nonclassical antifolates that optimizes inhibition of thymidylate biosynthesis with a favorable safety profile and extends survival in a pancreatic xenograft tumor mouse model and an hTS/Ink4a/Arf–/– genetically engineered spontaneous mouse tumor model. This evidence concerns the gene APCDD1 and neoplasm.